Twist Bioscience Corporation
TWST | NASDAQ
$142.74
-$10.04 (-6.57%)
Nov 2, 2026, 10:32 AM ET · Market open
Company Profile
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Key Executives
| Name | Position |
|---|---|
| Emily Marine Leproust | Co-Founder, Board Chair & Chief Executive Officer |
| Adam Laponis | Chief Financial Officer |
| Dennis Cho | Chief Legal Officer & Corporate Secretary |
| Michael Fero | Chief Information Officer |
| Patrick John Finn | President & Chief Operating Officer |
| Siyuan Chen | Chief Technology Officer |
| Colby Souders | Chief Scientific Officer |
| Nicole Moreno | Senior Vice President of Sales & Support |
| Paula Green | Senior Vice President of Human Resources |
| Robert F. Werner | Vice President & Chief Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 25, 2026 | 4 | Filing |
| Sep 23, 2026 | 4 | Filing |
| Sep 23, 2026 | 4 | Filing |
| Sep 23, 2026 | 4 | Filing |
| Sep 21, 2026 | 4 | Filing |
| Sep 10, 2026 | 4 | Filing |
| Sep 10, 2026 | 4 | Filing |
| Sep 10, 2026 | 4 | Filing |
| Sep 10, 2026 | 4 | Filing |
| Sep 08, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Twist Bioscience Corporation
| Country | United States |
| IPO Date | Oct 31, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 979 |
| CEO | Emily Marine Leproust |
Contact Details
681 Gateway Boulevard South San Francisco,
California 94080 United States
Stock Details
| Ticker Symbol | TWST |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001581280 |
| CUSIP Number | 90184D100 |
| ISIN Number | US90184D1000 |
| SIC Code | 2836 |
Recent News
- 1 month ago / benzinga.comTwist Bioscience Stock Hits New High, Then Retreats: What's Happening?
- 1 month ago / fool.comWhy Twist Bioscience Stock Skyrocketed This Week
- 2 months ago / benzinga.comBeyond Hype: Twist Bioscience Secures Data Pipeline Role In Eli Lilly TuneLab Ecosystem
- 2 months ago / gurufocus.comTwist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery
- 2 months ago / seekingalpha.comTwist Biosciences: AI-Driven Rally Or Short Squeeze? I'm Neutral (For Now)
- 2 months ago / benzinga.comTwist Bioscience Stock Resilient Despite Scorpion Capital Short Report
- 3 months ago / seekingalpha.comTwist Biosciences: Accelerating Growth, Diminishing Margin Of Safety
- 3 months ago / gurufocus.comTwist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock
- 3 months ago / businesswire.comTwist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock
- 3 months ago / seekingalpha.comTwist Bioscience Corporation (TWST) Q3 2026 Earnings Call Transcript
Add to Watchlist
Select watchlists to add or remove TWST